Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer Academic Article uri icon

Overview

MeSH Major

  • Enzyme Inhibitors
  • Hematologic Neoplasms
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Neoplasm Recurrence, Local
  • Neoplasms

abstract

  • Oral SAHA has linear pharmacokinetics and good bioavailability, inhibits histone deacetylase activity in PBMNCs, can be safely administered chronically, and has a broad range of antitumor activity.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC1855284

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.14.167

PubMed ID

  • 15897550

Additional Document Info

start page

  • 3923

end page

  • 31

volume

  • 23

number

  • 17